Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
This treatment protocol will enable therapeutic use of Anascorp in the management of systemic manifestations of scorpion sting envenomation, in patients for whom antivenom would otherwise be unavailable. The working hypotheses are as follows:
- The investigational antivenom is safe as treatment of scorpion sting envenomation.
- The investigational antivenom is effective as treatment of scorpion sting envenomation.
Scorpion Sting Envenomation
Drug: Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation|
- Evaluate the adverse events profile of each patient [ Time Frame: immediately after treatment, 24 hrs and 14 days. ]
- Resolution of systemic signs of scorpion envenomation [ Time Frame: after treatment ]
|Study Start Date:||May 2005|
|Study Completion Date:||September 2010|
|Primary Completion Date:||September 2010 (Final data collection date for primary outcome measure)|
Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
Drug: Antivenin Centruroides (scorpion) F(ab)2 Anascorp™
three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
The purpose of this Open Label, Multi-Center Treatment Protocol, phase III trial is to examine the safety and efficacy of Anascorp, for treatment of patients envenomed by scorpion sting.
The treatment protocol, including up to 25 Arizona sites, increases the total number of subjects receiving Anascorp™, and can provide supplemental safety data for the review process. At the same time, it will prevent a public health crisis in rural Arizona by replacing the dwindling supply of local antivenom before an BLA is approved.
Patients who arrive at the emergency clinic presenting with scorpion sting symptoms will be evaluated for treatment with Anascorp.
Each patient who qualifies for entry into the study, according to inclusion/exclusion criteria, is assigned a patient number in sequential order of entry. Approximately 100 patients could be enrolled in the study per year.
After informed consent has been obtained, a baseline history and physical will be obtained and documented in the patient's chart. This will include an evaluation of the symptoms of systemic scorpion envenomation. The patient's vital signs (blood pressure, pulse and respiration) will be taken. The patient will be questioned as to concomitant medications. Demographic data will also be collected.
Three vials of Anascorp will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access. If clinically indicated by systemic signs, a second dose (one vial) will be administered if clinically indicated by systemic signs. One additional dose may be administered 30 minutes later if indicated by clinically significant signs of envenomation. When clinically significant signs have been absent for at least 30 minutes, a final physical assessment will take place and the patient will be discharged to home.
Twenty four hours and fourteen days after Anascorp™ treatment, all patients will be monitored for signs and symptoms of adverse events, including acute hypersensitivity reactions (anaphylactic and/or anaphylactoid reactions) and delayed serum sickness. All patients who received study drug will be included in the final analyses.
For the individual patient, the study starts at the time the consent is signed and ends at the 14 day telephone interview. The outcome is assessed 14 days after discharge by telephone interview.
Concomitant therapy and medications may be used at any time as needed. All concomitant medication must be documented in the CRF from time of entry into the study until the 14 day follow up telephone interview..
Please refer to this study by its ClinicalTrials.gov identifier: NCT00624078
|United States, Arizona|
|Casa Grande Regional Medical Center|
|Casa Grande, Arizona, United States, 85222|
|Chandler, Arizona, United States, 85224|
|Southeast Arizona Medical Center|
|Douglas, Arizona, United States, 85260|
|Mercy Gilbert Medical Center|
|Gilbert, Arizona, United States, 85297|
|Banner Thunderbird Medical Center|
|Glendale, Arizona, United States, 85306|
|Banner Baywood Medical Center|
|Mesa, Arizona, United States, 86206|
|Gila Health Resources|
|Morenci, Arizona, United States, 85540|
|Holy Cross Hospital|
|Nogales, Arizona, United States, 85621|
|Maricopa Medical Center|
|Phoenix, Arizona, United States, 85008|
|Phoenix Children's Hospital|
|Phoenix, Arizona, United States, 85016|
|John C. Lincoln|
|Phoenix, Arizona, United States, 85027|
|Mt. Graham Regional Medical Center|
|Safford, Arizona, United States, 85546|
|San Carlos Indian Hospital|
|San Carlos, Arizona, United States, 85550|
|Scottsdale, Arizona, United States, 85260|
|Tucson Medical Center|
|Tucson, Arizona, United States, 85712|
|University Medical Center|
|Tucson, Arizona, United States, 85724|
|St. Mary's Hospital|
|Tucson, Arizona, United States, 85745|
|Whiteriver IHS Hospital|
|Whiteriver, Arizona, United States, 85941|
|Principal Investigator:||Leslie Boyer, M.D||VIPER Institute|
|Study Chair:||Walter Garcia, M.D||Instituto Bioclon S.A. de C.V.|